FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
04/10/2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
|
|
04/07/2026
2026 National Sunscreen Partner
We are proud to share that burnd Sunscreen has joined AIM at Melanoma as our 2026 National Sunscreen Partner. This…
|
04/07/2026
Young Adult Cancer & Mental Health
In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha Siegel sits down with Dr. Victoria…
|
04/02/2026
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Presented in partnership with Save Your Skin Foundation and Ocumel CanadaOcumel Canada (OC), is powered by Save Your Skin Foundation,…
03/26/2026
Wade Watson, Stage III Melanoma Survivor
A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
|
03/26/2026
Advocates Renew Call for RP1 Approval
As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
|
03/03/2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Cancer is often spoken about in terms of diagnosis, treatment plans, and survival rates. But there is a quieter, more…
|
02/19/2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
|
|
02/05/2026
FDA Responds to Patient Advocacy on RP1 + Nivolumab
As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
|
02/05/2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
|
|
Recent Posts
Apr. 10, 2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
Apr. 07, 2026
2026 National Sunscreen Partner
Apr. 07, 2026
Young Adult Cancer & Mental Health
Apr. 02, 2026
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Mar. 26, 2026